Recent collaborations

In July 2017, Bristol-Myers Squibb (BMY) and Clovis Oncology (CLVS) entered into a clinical collaboration agreement to evaluate Bristol-Myers Squibb’s Opdivo and Clovis Oncology’s Rubraca combination therapy for the treatment of advanced ovarian cancer and advanced triple-negative breast cancers (or TNBC).

Bristol-Myers Squibb and Clovis Oncology plan to conduct the Phase 3 trial. This trial would evaluate the safety and efficacy of Rubraca and Opdivo combination therapy as a first-line maintenance treatment in newly diagnosed patients with stage 3/4 high-grade ovarian, fallopian tube, or primary peritoneal cancer. These patients must have undergone a platinum-based chemotherapy, compared to Rubraca therapy, Opdivo therapy, and placebo therapy.

Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

Bristol-Myers Squibb and Clovis Oncology also plan to conduct a Phase 3 pivotal trial. This trial would evaluate the safety and efficacy of Rubraca and Opdivo combination therapy as a first-line maintenance treatment in individuals with recurrent, locally advanced inoperable TNBC related with a homologous recombination deficiency (or HRD). This treatment would be compared with Rubraca therapy, Opdivo therapy, and chemotherapy.

The collaboration between Bristol-Myers Squibb and Clovis Oncology also includes a Phase 3 trial to evaluate the safety and efficacy of Rubraca and Opdivo combination therapy. This therapy would involve the treatment of individuals with metastatic castration-resistant prostate cancer (or mCRPC).

Analysts’ recommendations

Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

Around 43% of these analysts suggested some form of a “buy” rating. On August 15, 2017, Bristol-Myers Squibb had a consensus 12-month target price of $57.32. The Vanguard Health Care ETF (VHT) invests ~2.8% of its total portfolio in Bristol-Myers Squibb.

Peers’ ratings

Of the 22 analysts covering Pfizer (PFE) in August 2017, one analyst recommended a “strong buy,” while ten analysts suggested a “buy.” Ten analysts tracking Pfizer suggested a “hold,” while one analyst recommended a “strong sell.”

Around 50% of the analysts tracking Pfizer in August recommended some form of a “buy” rating. On August 15, Pfizer had a consensus 12-month target price of $37.45, which represents an ~12.4% return on investment.

Of the 22 analysts tracking Johnson & Johnson (JNJ) in August 2017, two analysts suggested a “strong buy,” and eight analysts suggested a “buy.” Ten analysts tracking Johnson & Johnson recommended a “hold,” one analyst recommended a “sell,” and one analyst recommended a “strong sell.”

Around 50% of the analysts tracking JNJ in August 2017 recommended some form of a “buy” rating. In August, Johnson & Johnson had a consensus 12-month target price of $137.05, which represents an ~2.7% return on investment.

Latest articles

German chip maker Infineon Technologies has reportedly raised 1.55 billion euros (~$1.74 billion) in capital by selling its shares to fund its acquisition of Cypress Semiconductor (CY). Infineon has sold ~113 million new shares at 13.70 euros each.

As of June 18, Dunkin’ Brands (DNKN) was trading at $80.07, an 8.9% rise since reporting its first-quarter earnings on May 2. Also, DNKN was trading at a premium of 29.8% from its 52-week low of $61.69 and a discount of 1.6% from its 52-week high of $81.40.

19 Jun

Are Lower Oil Prices Weighing on ExxonMobil Stock?

WRITTEN BY Maitali Ramkumar

ExxonMobil (XOM) stock has fallen 7.1% in the second quarter so far. Let's review ExxonMobil's stock performance in comparison to oil price changes and equity market movements in the quarter.

19 Jun

As Facebook Unveils Libra, MSFT and CRM Join a Blockchain Group

WRITTEN BY Mayur Sontakke, CFA, FRM

On June 18, Facebook (FB) launched Libra, its own cryptocurrency. On the same day, CoinDesk published another piece of blockchain news that didn’t receive as much fanfare as Facebook’s Libra news. Was the timing a coincidence? We think not.

Uber Technologies (UBER) has picked Melbourne as another test site for its flying taxi service known as UberAir. The Australian city is the first international test site Uber has chosen for its flying taxi service. The addition of Melbourne brings the number of test locations Uber has picked for its UberAir service to three.

Lyft (LYFT) and Uber Technologies (UBER) are pushing back against California legislation that would require them to recognize their drivers as employees rather than independent contractors. The legislation would require companies like Lyft to give their drivers the compensation and benefits spelled out under California’s employment regulations.

172.31.16.229